Trials / Active Not Recruiting
Active Not RecruitingNCT05433584
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 780 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirzepatide | Administered SC |
| DRUG | Antihyperglycemic medication | As prescribed |
Timeline
- Start date
- 2022-08-01
- Primary completion
- 2025-10-21
- Completion
- 2027-11-01
- First posted
- 2022-06-27
- Last updated
- 2025-12-12
Locations
90 sites across 11 countries: United States, Argentina, Canada, Germany, Israel, Italy, Mexico, Puerto Rico, Romania, Slovakia, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05433584. Inclusion in this directory is not an endorsement.